Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Accuray

Related ARAY
Earnings Scheduled For August 21, 2014
What Falling Estimates & Price Mean for Oxford Immunotec Global (OXFD) - Tale of the Tape

In a report published Friday, Jefferies & Company reiterated its Buy rating on Accuray (NASDAQ: ARAY), but lowered its price target from $10.00 to $6.50.

Jefferies noted, “Accuray posted preliminary F2Q results well below expectations and drastically reduced its F13 guidance. The reset under new management was expected but the severity was a surprise. Valuation is set to move into distressed territory, unwarranted given that our thesis is delayed but intact. Lowering estimates and PT but maintaining Buy.”

Accuray closed on Thursday at $6.78.

Latest Ratings for ARAY

DateFirmActionFromTo
Jun 2014JP MorganUpgradesNeutralOverweight
Mar 2014BTIG ResearchInitiates Coverage onBuy
Jan 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ARAY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARAY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters